Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
Portfolio Pulse from
Precigen's BLA for PRGN-2012 for Recurrent Respiratory Papillomatosis has been accepted by the FDA with a Priority Review date set for August 27, 2025. Approval would be significant as there are no FDA-approved drugs for RRP, affecting 27,000 people in the US. Precigen is also seeking partnerships to advance its UltraCAR-T technology.
February 28, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen's BLA for PRGN-2012 has been accepted by the FDA, with a Priority Review date in 2025. Approval could be significant due to the lack of FDA-approved treatments for RRP. Precigen is also looking for partnerships to advance its UltraCAR-T technology.
The acceptance of the BLA with a Priority Review indicates a potentially faster path to market, which is positive for PGEN. The lack of existing FDA-approved treatments for RRP highlights the potential market opportunity. Additionally, the pursuit of partnerships for UltraCAR-T suggests strategic growth plans.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100